CN103610065A - 一种海参玛咖组合物及其制备方法 - Google Patents
一种海参玛咖组合物及其制备方法 Download PDFInfo
- Publication number
- CN103610065A CN103610065A CN201310665617.0A CN201310665617A CN103610065A CN 103610065 A CN103610065 A CN 103610065A CN 201310665617 A CN201310665617 A CN 201310665617A CN 103610065 A CN103610065 A CN 103610065A
- Authority
- CN
- China
- Prior art keywords
- sea cucumber
- powder
- agate coffee
- preparation
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000251511 Holothuroidea Species 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims description 18
- 240000000759 Lepidium meyenii Species 0.000 title abstract description 5
- 235000000421 Lepidium meyenii Nutrition 0.000 title abstract description 5
- 235000012902 lepidium meyenii Nutrition 0.000 title abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 52
- 235000005976 Citrus sinensis Nutrition 0.000 claims abstract description 11
- 240000002319 Citrus sinensis Species 0.000 claims abstract description 11
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 10
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 10
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 10
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 10
- 230000036039 immunity Effects 0.000 claims abstract description 5
- 240000007154 Coffea arabica Species 0.000 claims description 52
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 52
- 244000194101 Ginkgo biloba Species 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 12
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 9
- 241000219780 Pueraria Species 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- -1 pulvis Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 235000020985 whole grains Nutrition 0.000 claims description 4
- 239000007910 chewable tablet Substances 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 239000007887 hard shell capsule Substances 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 230000035558 fertility Effects 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 239000009429 Ginkgo biloba extract Substances 0.000 abstract 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000002929 anti-fatigue Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229930188089 Holothurin Natural products 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- MAWWITJOQDJRJF-ADBICINLSA-M holothurin Chemical compound [Na+].O[C@@H]1[C@@H](OC)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H](OC[C@H]([C@@H]3O)OS([O-])(=O)=O)O[C@@H]3C([C@H]4[C@](C=5[C@H]([C@@]6(CC[C@]7(O)[C@](C)([C@H]8OC(C)(C)CC8)OC(=O)[C@@]76[C@@H](O)C=5)C)CC4)(C)CC3)(C)C)O[C@@H]2C)O)O[C@H](C)[C@H]1O MAWWITJOQDJRJF-ADBICINLSA-M 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 241000965254 Apostichopus japonicus Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 125000004383 glucosinolate group Chemical group 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005186 women's health Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003005 anti-senility effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/08—Food product presented as a kit of parts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
- A23V2250/2042—Marine animal, fish extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2122—Gingko Biloba
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种海参玛咖组合物。该组合物包括海参速溶粉、玛咖粉、银杏叶提取物、怀山药粉、松花粉和甜橙粉,由上述组分混合制备而成。海参玛咖组合物具有提高免疫力,调节肌体新陈代谢,增强体力,增强生育能力,抗疲劳等多种功效。
Description
技术领域
本发明涉及保健品领域,具体涉及一种海参玛咖的组合物制剂及其制备方法。
背景技术
海参
海参不仅是珍贵的食品,也养生治病保健的名贵药材。民间验方中,不同种类的海参,都可以直接入药治病。
近年来研究证实,海参可促进人体控制感染过程的前列腺素的分泌,关节炎患者进补海参,可补充所必需的粘多糖和软骨素等,这也即是千年前的古人就用海参入药治疗骨关节疾病道理所在;海参特有的活性物质海参素,对多种真菌有显著的抑制作用,刺参素A和B可用于治疗真菌和白癣菌感染,具有显著的抗炎、成骨作用,尤其对肝炎患者、结核病、糖尿病、心血管病有显著的治疗作用;海参具有珍贵的海参素,它的分子结构似皂甙,是羟甾烷衍生物的配糖体,它的药用保健价值极高,科学研究证明,它对中风痉孪性麻痹有明显的治疗作用。
通过药理实验证明,刺参粘多糖具有广谱的抗肿瘤作用,能抑制癌细胞的生长与转移,对恶性肿瘤的生长、转移具有显著抑制作用,临床上已广泛应用于肝癌、肺癌、胃癌、鼻咽癌、骨癌、淋巴癌、卵巢癌、子宫癌、乳腺癌、白血病、脑瘤及术后转移复发的良性、恶性瘤等患者的治疗。
多糖是海参体壁的另一类重要成分。其含量可占干参总有机物的6%以上。最高可达25%。海参的多糖含量及组成等是衡量海参营养价值的最重要的化学指标。不同种类的海参或同种海参不同生长期及同种海参的不同组织中海参多糖的含量都是有很大的差别的。海参多糖含量,组成及硫酸酯化程度是判别海参优劣的关键指标。
海参粘多糖主要存在于海参体细胞外的细胞间质中。海参粘多糖的性质;不易溶解于水和酸,但溶于弱碱。因此海参的加工应避免碱性环境中进行,否则海参的活性物质会大量流失。
海参体壁多糖主要有两种,一为海参糖胺多糖或粘多糖,系一种由D-N乙酰氨基关乳糖、D葡萄糖醛酸和L岩藻糖组成的分支杂多糖,查对分子量在4--5万左右。另一种海参岩藻多糖,是由L岩藻构成的直链匀多糖。相对分子量在8--10万左右。两者的组成糖基虽不同,但他们的糖链上都有部分羟基发生硫酸酯化,并且硫酸酯占多糖含量约32%。
近三十年来国内外对海参多糖特别是对粘多糖(HG)及其改构物(如解聚物DHG)进行了广泛的药理研究,证实了它有多种药效。
一般人群都能食用。
1.适宜虚劳羸弱,气血不足,营养不良,病后产后体虚之人食用;适宜肾阳不足,阳痿遗精,小便频数之人食用;适宜高血压病,高脂血症,冠心病,动脉硬化之人食用;适宜癌症病人及放疗、化疗、手术后食用;适宜肝炎,肾炎,糖尿病患者及肝硬化腹水和神经衰弱者食用;适宜血友病患者及易于出血之人食用;适宜年老体弱者食用;
2.患急性肠炎、菌痢、感冒、咳痰、气喘及大便溏薄、出血兼有瘀滞及湿邪阻滞的患者忌食。
3.生血养血和促进钙质吸收。
4.预防心血管疾病,增强人体免疫力者。
5.手术患者的最佳补品,孕产妇的保健,美容养颜。
玛咖
玛咖(MACA)属十字花科植物,果实呈卵形且小,根茎肥大,形似萝卜,世界玛咖的主产国是中国和秘鲁。玛咖生长的自然条件极其苛刻和独特,在低湿、强风、昼夜40度温差下的贫瘠土地上可以存活,耐寒、耐旱、抗洪涝,被国际植物学界专家誉为不可多得的优良物种。
1992年联合国粮食组织(FAO)将玛咖作为营养补充剂向世界推荐。2001年美国食品与药品管理局(FDA)通过了玛咖保健品进入美国。其后,美国NDSA(美国太空总署)和UIAA(国际登山组织联盟)把玛咖列为必备的营养品。国际奥委会药品检测中心对玛咖已经做出不含任何违禁元素的检测结论,并向各国运动员推荐使用
玛咖成分:玛咖富含55种天然营养素,加工成产品时无须添加任何化学添加物。新鲜玛咖含水分10.4%、蛋白质10.2%、脂肪2.2%、碳水化合物59%、纤维21.3%。其蛋白质含有丰富的人体必需氨基酸,如:精氨酸(9.94%)、天门冬氨酸(9.17%)谷氨酸(15.6%)和赖氨酸(54.5%)等。玛咖的脂肪酸中不饱和脂肪酸的含量占52.7%(其 中 亚 由 酸 18.5%、亚 麻 酸 8.87%),还 含 有 芥 子 油 苷(glucosinolates)甾醇和钾、钙、铁等。玛咖烯和玛咖酰胺是玛咖中的独特元素,是实现玛咖功效的核心物质,可以给人和动物带来非同寻常的活力。检测结果表明:玛咖的营养价值超越了冬虫夏草、人参,是真正可以放心食用的天然功能性食品。
玛咖药理作用:华中科技大学生命科学与技术学院的余龙江教授在《南美植物玛咖的研究进展》一文中对玛咖药理作用做了以下说明。
一.抗疲劳作用
玛咖根粉末中含有丰富的氨基酸、牛磺酸、矿物质锌等抗疲劳营养物质。如支链氨基酸(亮氨酸、缬氨酸、异亮氨酸)在消除运动性中枢疲劳和机体疲劳中有重要作用;锌则通过激活神经内分泌激素、能量代谢所涉及的有关酶如乳酸脱氢酶等控制核酸、蛋白质、糖和脂肪的代谢过程,起到抗疲劳作用。
二.提高生育能力
玛咖提高生育力的机制可能是提高动物成熟卵泡小体的数量、精子的流动性和精子的数量,这与玛咖中含有的生物碱、丰富的精氨酸和果糖等关系密切。玛咖中生物碱可以刺激生殖系统,增加卵泡小体和精子数量;精氨酸是精子中氨基酸主要的组成成分,可以提高精子的运动性,从而提高机体生育能力;而果糖则可以为精子提供能力。
三.改善性功能 抗疲劳 抗衰老
美国植物学家Zhang BL等人从玛咖中发现了化学成分玛咖酰胺与玛咖烯,并通过药理实验证明这两类物质具有平衡男女身体荷尔蒙的分泌,修复生理机能、抗衰老、抗疲劳和增强性功能的作用,玛咖属于纯绿色天然食品,安全无污染,又被称为“天然荷尔蒙发动机”。
四.抗肿瘤作用
实验证明,玛咖内含有的异硫氰酸苄酯与芥子油苷形成的天然混合物是有效的抗癌物质;此外,玛咖中含有的多不饱和脂肪酸和Vc也有一定抗癌作用。
五.其他作用
玛咖可用于治疗慢性疲劳综合症、抑郁症,这与玛咖调节内分泌作用有关;玛咖传统上还用于治疗哮喘症,这与玛咖中含有的类固醇以及促肾上腺素类物质有关;玛咖还可以预防各种类型的贫血,这与玛咖的高营养尤其是含有的矿物质如钙、铁密不可分。
银杏叶提取物(Ginko Biloba Extract,GBE)是以银杏Ginkgo biloba L.的叶为原料,采用适当的溶剂,提取的有效成分富集的一类产品。银杏叶提取物的药用价值与应用极为广泛。采用先进的技术、工艺和设备,通过进一步提取、分离和纯化,其药理作用更加明显,除具有显著的拮抗PAF受体外,还可以在抗炎、抗过敏、扩张血管、保护心脑血管、改善外周血液循环、降低血清胆固醇及辅助抗癌等方面发挥药效,可以广泛应用于心脑血管、神经等系统疾病的防治和保健。
怀山药:现代药理研究证实,怀山药具有营养滋补、诱生搅扰素、增强机体免疫力、调度内排泄、补气通脉、镇咳祛痰、平喘等功能,能改善冠状动脉及微循环血流,可治疗慢性气管炎、冠心病、心绞痛等。
松花粉
松花粉中含有人体所需的 200 多种营养元素。其中 22 种 氨 基 酸、 15 种维生素 、 30 多种矿物质、 100 多种酶,以及核酸、不饱和脂肪酸、卵磷脂、类黄铜、单糖、多糖等。松花粉的营养成分不仅种类全面,且含量也非常高。其中蛋白质总含量是牛肉鸡蛋的 7 到 10 倍;铁比菠菜高出 20 倍; V a 原型胡萝卜素比胡萝卜多 20 到 30 倍。松花粉中营养成份含量比例搭配合理。例如 8 种必需氨基酸,有的人体需要多,有的需要少,世界卫生组织和粮农组织对它们的需求含量都做出了规定。而松花粉中的含量与它们的规定是基本一致。
发明内容
本发明的目的在于提供一种可以提高免疫力,调节肌体新陈代谢,增强体力,增强生育能力,抗疲劳的海参玛咖营养保健品。
为了上述目的,本发明通过实践研究,提供了一种海参玛咖组合物,该组合物包括海参速溶粉、玛咖粉、银杏叶提取物、怀山药粉、松花粉和甜橙粉,由上述组分混合制备而成。本发明中的海参速溶粉。保留海参原有的有效成分,具有纯度高,速溶,吸收好等特点,保留了海参原有的所有功效。
上述海参玛咖组合物的原料配比为:
海参速溶粉15.0---30.0份;
玛咖粉35.0---55.0份;
银杏叶提取物10-30份;
怀山药粉5-20份;
松花粉25—45.0份;
甜橙粉1.0—4.0份。
上述组合物制剂可以为散剂、粉剂、颗粒剂、胶囊剂、片剂。优选为片剂、颗粒剂。
组合物制剂,可以将片剂制备成糖果压片、咀嚼片、泡腾片、普通压片等。上述组合物制剂,可以将胶囊剂制备成软胶囊、硬胶囊等剂型。
一种海参玛咖组合物的制备方法:其特征在于包括如下步骤:
1: 双酶降解加工制备海参粉(海参速溶粉);
2: 超微粉碎制备玛咖粉;
3:按照比例将海参速溶粉,已粉碎的玛咖超细粉、已检验合格的银杏叶提取物、怀山药粉、松花粉,按配方要求,称定重量。
4:称量的各原料,在三维混合机中,混合均匀。
5:制粒:用低醇做湿润剂,按照常规制粒方法制粒,然后进行干燥。
6:整粒:将甜橙粉混入颗粒中,混合均匀。
本发明可将步骤6中所得的混合物离加入适量的色拉油研磨均匀,按软胶囊生产工艺流程制成软胶囊制剂。
本发明中还可将步骤6所得的混合物按硬胶囊生产工艺流程制成硬胶囊制剂。
本发明还可以将步骤6所得的混合物,加入相应的辅料,压片制成咀嚼片剂。
实施例
实施例1:海参粉(海参速溶粉)双酶降解的加工工艺
步骤A:首先将从大海捞出的新鲜刺海参,洗净、剪开,除去内脏的参体壁。海参体壁内含有海参自溶酶的液体留作备用、并将海参内脏中的海参肠和海参花中的杂质除净,海参肠和海参花一并应用。
步骤B:将海参体壁、海参肠和海参花粉碎后球磨打浆,加入酶解罐中,加海参体壁重量的5-10倍的水。
步骤C:加入海参体壁内含有海参自溶酶的液体和风味酶适量,混合均匀,打开蒸汽开关,渐渐升温至45-65度,在不断搅拌的条件下。维持恒温3.5-4小时。待整个液体基本澄清,升温至100度,5-10分钟,降温后过滤;
步骤D:将上述步骤C中的液体,加水调整浓度,浓度在2%-10%。用洁净喷干塔。进行喷雾干燥。
步骤E:喷干粉检验合格,塑料袋抽真空包装,低温保存,备用。
实施例2:玛咖粉的加工工艺:
选购资质合格的玛咖原料。
玛咖原料经化验合格,经过YSC-701超微粉碎机,此方法的特点的细度高,粉碎过程中最高温度只有45度。保证了对原料的质量不受破坏。粉末损失极微,也无污染。
实施例3:取松花粉、银杏叶提取物、怀山药粉按标准检验功效成分合格。检测重金属等指标合格。
实施例4:组合物的制备
1:称取海参速溶粉15.0kg、玛咖粉35.0kg、银杏叶提取物10kg、怀山药粉5kg、松花粉25kg、甜橙粉1.0kg。
2:称量的各原料,在三维混合机中,混合均匀。
3:制粒:用低醇做湿润剂,按照常规制粒方法制粒,然后进行干燥。
4:整粒:将甜橙粉混入颗粒中,混合均匀。
5:压片。
6:检验合格后,包装。
实施例5:
1:称取海参速溶粉30kg、玛咖粉55kg、银杏叶提取物30kg、怀山药粉20kg、松花粉45kg、甜橙粉4kg。
2:称量的各原料,在三维混合机中,混合均匀。
3:制粒:用低醇做湿润剂,按照常规制粒方法制粒,然后进行干燥。
4:整粒:将甜橙粉混入颗粒中,混合均匀。
5:压片。
6:检验合格后,包装。
Claims (8)
1.一种海参玛咖组合物,其特征在于该组合物由海参速溶粉、玛咖粉、银杏叶提取物、怀山药粉、松花粉和甜橙粉组成。
2.如权利要求1所述的海参玛咖组合物,其特征在于海参速溶粉15.0-30.0份、玛咖粉35.0-55.0份、银杏叶提取物10-30份、怀山药粉5-20份、松花粉25—45.0份、甜橙粉1.0—4.0份。
3.如权利要求1或2所述的海参玛咖组合物,其特征在于所述制剂可以为散剂、粉剂、颗粒剂、胶囊剂、片剂。
4.如权利要求1或2所述的海参玛咖组合物,其特征在于所述制剂为片剂、胶囊剂。
5.如权利要求3或4所述的海参玛咖组合物,其特征在于将所述制剂制备成糖果压片、咀嚼片、泡腾片、普通压片等。
6.如权利要求3或4所述的组合物制剂胶囊剂制备成软胶囊、硬胶囊等剂型。
7.如权利要求1所述的一种海参玛咖组合物的制备方法:
(1) 双酶降解加工制备海参粉(海参速溶粉);
(2)超微粉碎制备玛咖粉;
(3)按照比例将海参速溶粉,已粉碎的玛咖超细粉、已检验合格的银杏叶提取物、怀山药粉、松花粉,按配方要求,称定重量。
(4)称量的各原料,在三维混合机中混合均匀。
(5)制粒:用低醇做湿润剂,按照常规制粒方法制粒,然后进行干燥。
(6)整粒:将甜橙粉混入颗粒中,混合均匀。
8. 如权利要求1所述的一种海参玛咖组合物在制备增强免疫力保健品中的应用。
。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310665617.0A CN103610065A (zh) | 2013-12-11 | 2013-12-11 | 一种海参玛咖组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310665617.0A CN103610065A (zh) | 2013-12-11 | 2013-12-11 | 一种海参玛咖组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103610065A true CN103610065A (zh) | 2014-03-05 |
Family
ID=50160801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310665617.0A Pending CN103610065A (zh) | 2013-12-11 | 2013-12-11 | 一种海参玛咖组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103610065A (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104187628A (zh) * | 2014-08-12 | 2014-12-10 | 安徽阳光药业有限公司 | 一种虫草玛咖片及其制备方法 |
CN104256607A (zh) * | 2014-10-11 | 2015-01-07 | 威海力元海洋生物科技有限公司 | 一种海参雪莲养生制品 |
CN104352542A (zh) * | 2014-10-11 | 2015-02-18 | 威海力元海洋生物科技有限公司 | 一种海参雪莲的组合物制剂及其制备方法 |
CN104544104A (zh) * | 2015-02-11 | 2015-04-29 | 昆明轿子雪山玛卡生物科技开发有限公司 | 一种玛卡与海狗油复合软胶囊 |
CN104543652A (zh) * | 2015-01-06 | 2015-04-29 | 北京蜜蜂堂生物医药股份有限公司 | 一种玛咖花粉及其制备方法 |
CN104642699A (zh) * | 2015-02-13 | 2015-05-27 | 佛山市宝资林生物科技有限公司 | 一种补气壮阳养生压片糖果的制作方法 |
CN104738638A (zh) * | 2015-01-09 | 2015-07-01 | 李晨悦 | 具有抗疲劳作用的组合物及其用途 |
CN104997829A (zh) * | 2015-07-02 | 2015-10-28 | 宁波佳康生物科技有限公司 | 一种抗疲劳组合物及含有该组合物的保健食品 |
CN104997122A (zh) * | 2015-08-14 | 2015-10-28 | 青岛浩大海洋保健食品有限公司 | 一种滋阴壮阳玛卡复合保健饮料 |
CN105053452A (zh) * | 2015-08-04 | 2015-11-18 | 大连棒棰岛海产股份有限公司 | 含有海参及玛咖成分的糖果制品 |
CN105494851A (zh) * | 2015-12-02 | 2016-04-20 | 阿衣吐拉·阿不力米提 | 一种适合女性的玛咖抗疲劳糖果及其生产工艺 |
CN107319541A (zh) * | 2017-06-06 | 2017-11-07 | 福建省泽弘智能机械有限公司 | 一种不加辅料的复方玛咖片及其制备方法 |
CN107772439A (zh) * | 2016-08-24 | 2018-03-09 | 江苏康缘药业股份有限公司 | 一种含玛咖桂圆的中药组合物及其咀嚼片 |
CN110772541A (zh) * | 2018-07-31 | 2020-02-11 | 成都百裕制药股份有限公司 | 预防和/或治疗男性性功能障碍的组合物及其制剂、应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1475168A (zh) * | 2003-07-09 | 2004-02-18 | 大连鸿宇药业有限公司 | 可提高机体免疫力的保健食品及制作方法 |
CN101361578A (zh) * | 2008-09-25 | 2009-02-11 | 大连工业大学 | 海参卵营养品及其制备方法 |
CN101612337A (zh) * | 2009-07-17 | 2009-12-30 | 邵梦扬 | 增强免疫力的中药保健品 |
CN102335220A (zh) * | 2011-10-09 | 2012-02-01 | 朱晓西 | 玛咖海参王抗癌增强免疫制剂 |
CN102907558A (zh) * | 2012-11-16 | 2013-02-06 | 山东省海洋水产研究所 | 一种海参多肽的加工方法 |
-
2013
- 2013-12-11 CN CN201310665617.0A patent/CN103610065A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1475168A (zh) * | 2003-07-09 | 2004-02-18 | 大连鸿宇药业有限公司 | 可提高机体免疫力的保健食品及制作方法 |
CN101361578A (zh) * | 2008-09-25 | 2009-02-11 | 大连工业大学 | 海参卵营养品及其制备方法 |
CN101612337A (zh) * | 2009-07-17 | 2009-12-30 | 邵梦扬 | 增强免疫力的中药保健品 |
CN102335220A (zh) * | 2011-10-09 | 2012-02-01 | 朱晓西 | 玛咖海参王抗癌增强免疫制剂 |
CN102907558A (zh) * | 2012-11-16 | 2013-02-06 | 山东省海洋水产研究所 | 一种海参多肽的加工方法 |
Non-Patent Citations (2)
Title |
---|
刘春华等: "中药延缓衰老的作用", 《特产研究》, no. 01, 30 March 2001 (2001-03-30) * |
赖桂萍等: "松花粉药理作用及临床应用研究概况", 《中国实用医药》, no. 28, 31 October 2011 (2011-10-31) * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104187628A (zh) * | 2014-08-12 | 2014-12-10 | 安徽阳光药业有限公司 | 一种虫草玛咖片及其制备方法 |
CN104256607A (zh) * | 2014-10-11 | 2015-01-07 | 威海力元海洋生物科技有限公司 | 一种海参雪莲养生制品 |
CN104352542A (zh) * | 2014-10-11 | 2015-02-18 | 威海力元海洋生物科技有限公司 | 一种海参雪莲的组合物制剂及其制备方法 |
CN104543652A (zh) * | 2015-01-06 | 2015-04-29 | 北京蜜蜂堂生物医药股份有限公司 | 一种玛咖花粉及其制备方法 |
CN104738638A (zh) * | 2015-01-09 | 2015-07-01 | 李晨悦 | 具有抗疲劳作用的组合物及其用途 |
CN104544104A (zh) * | 2015-02-11 | 2015-04-29 | 昆明轿子雪山玛卡生物科技开发有限公司 | 一种玛卡与海狗油复合软胶囊 |
CN104642699A (zh) * | 2015-02-13 | 2015-05-27 | 佛山市宝资林生物科技有限公司 | 一种补气壮阳养生压片糖果的制作方法 |
CN104997829A (zh) * | 2015-07-02 | 2015-10-28 | 宁波佳康生物科技有限公司 | 一种抗疲劳组合物及含有该组合物的保健食品 |
CN105053452A (zh) * | 2015-08-04 | 2015-11-18 | 大连棒棰岛海产股份有限公司 | 含有海参及玛咖成分的糖果制品 |
CN104997122A (zh) * | 2015-08-14 | 2015-10-28 | 青岛浩大海洋保健食品有限公司 | 一种滋阴壮阳玛卡复合保健饮料 |
CN105494851A (zh) * | 2015-12-02 | 2016-04-20 | 阿衣吐拉·阿不力米提 | 一种适合女性的玛咖抗疲劳糖果及其生产工艺 |
CN107772439A (zh) * | 2016-08-24 | 2018-03-09 | 江苏康缘药业股份有限公司 | 一种含玛咖桂圆的中药组合物及其咀嚼片 |
CN107319541A (zh) * | 2017-06-06 | 2017-11-07 | 福建省泽弘智能机械有限公司 | 一种不加辅料的复方玛咖片及其制备方法 |
CN110772541A (zh) * | 2018-07-31 | 2020-02-11 | 成都百裕制药股份有限公司 | 预防和/或治疗男性性功能障碍的组合物及其制剂、应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103610065A (zh) | 一种海参玛咖组合物及其制备方法 | |
CN101253903B (zh) | 一种具有减肥功能的保健食品及其制备方法 | |
CN102524408A (zh) | 一种营养豆浆及其制备方法 | |
CN105433201A (zh) | 均衡营养主食面粉及其制备方法 | |
CN101579120A (zh) | 一种具有减肥功能的营养食品及其制备方法 | |
CN105124276B (zh) | 养蟹饲料 | |
CN109939143A (zh) | 一种用于降血糖控制并发症的中药组合物及其制备方法 | |
KR20120124608A (ko) | 인삼씨오일을 주로 하는 건강보조식품 | |
CN107048386A (zh) | 一种性功能调节保健食品 | |
CN102551046A (zh) | 一种天然减肥保健组合物及其应用 | |
CN103584098A (zh) | 玛咖杏仁片及其制备方法 | |
CN109275856A (zh) | 一种灵芝食品 | |
CN111184214A (zh) | 酵素胶原蛋白杂粮果蔬即食代餐粥及其制作方法 | |
CN110583974A (zh) | 一种瘦身全谷营养健康代餐食品及其制备方法 | |
Mittal et al. | A Critical Review on Ethnobotanical and Pharmacological Aspects of Euryale Ferox Salisb. | |
CN101991110B (zh) | 野生灵芝系列食品 | |
CN105056005B (zh) | 一种能降脂减肥的药食同源组合物 | |
CN112704717A (zh) | 一种辅助晚期消化道肿瘤治疗的健胃药食组合物 | |
CN101176495A (zh) | 中药果汁滋补颗粒与糖片及其制备工艺 | |
CN110638038A (zh) | 一种用于控制高血糖的医学配方营养代餐粉及其制备方法 | |
CN102441069A (zh) | 一种益生元长寿片及其制备方法 | |
CN108013459A (zh) | 一种具有减肥美容功能的保健食品及其制备方法 | |
CN103933146A (zh) | 一种可调节人体免疫力的花粉制品 | |
CN103181557A (zh) | 具有减肥功能的营养食品及其制备方法 | |
CN112401226A (zh) | 一种保健食品及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140305 |